Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258854 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL5466112 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL11106021 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL14754192 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL9083343 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| Hydrochloric Acid SCHEMBL29999389 | 0.98 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL11106907 | 0.96 | MEN1 (0.48) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL12479041 | 0.96 | MEN1 (0.48) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL12479042 | 0.96 | MEN1 (0.48) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL11106393 | 0.96 | MEN1 (0.48) | ALDH1A1MEN1KMT2APKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-116134035-B | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250042919-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-113603683-B | Substituted phenyl oxazolidinones for antimicrobial treatment | 结核病药物开发全球联盟公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005095339-A1 | DICYANOPYRROLIDINES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0330108-B1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5081237-A | Chemical intermediates for bactericides | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4923857-A | CARBAPENICILLINS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| EP-0330108-A1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
| US-3951980-A | 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes | STANFORD RESEARCH INSTITUTE (US) | 1976-04-20 | — | — | US | disclosed |
| US-3947445-A | Diazabicyclooctanes and diazabicycloheptanes | STANFORD RESEARCH INSTITUTE (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | ALDH1A1 2990/4885MEN1 3200/4885KMT2A 1301/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | ALDH1A1 1000/4885MEN1 2884/4885KMT2A 391/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 908/4885MEN1 1822/4885KMT2A 872/4885 |
| US-20250042919-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | ALDH1A1 1402/4885MEN1 2908/4885KMT2A 2044/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | ALDH1A1 1000/4885MEN1 2884/4885KMT2A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.